This review discusses advances in evidence-based treatment of acute myeloid leukemia with molecularly targeted drug therapy.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Current Management of Desmoid Tumors | 0 | 9.48 | 01-08-2024 |
| 2 | Race and Ethnicity and Overall Survival in Pediatric Acute Myeloid Leukemia | 0 | 5.63 | 12-08-2026 |
| 3 | Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors | 0 | 4.57 | 01-09-2023 |
| 4 | Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer | 0 | 7.64 | 01-10-2024 |
| 5 | Immune Checkpoint Inhibitors for Child-Pugh B Hepatocellular Carcinoma | 0 | 11.22 | 01-10-2023 |
| 6 | Cardiotoxicity of Immune Checkpoint Inhibitors | 0 | 8 | 01-10-2024 |
| 7 | PARP Inhibitors for Breast Cancer Treatment | 0 | 5.63 | 01-05-2024 |
| 8 | Современные подходы и возможности в выборе терапии ALK+ НМРЛ | 0 | 10.06 | 21-01-2026 |
| 9 | No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma | 0 | 11.26 | 13-08-2026 |